Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-6.74% $0.512
America/New_York / 28 mar 2024 @ 14:54
FUNDAMENTALS | |
---|---|
MarketCap: | 50.46 mill |
EPS: | -0.480 |
P/E: | -1.070 |
Earnings Date: | Mar 28, 2024 |
SharesOutstanding: | 98.56 mill |
Avg Daily Volume: | 0.420 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | ||
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.070 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.18x |
Company: PE -1.070 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.254 (144.86%) $0.742 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 0.461 - 0.563 ( +/- 9.96%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Fair John A | Buy | 290 000 | Employee Stock Option (right to buy) |
2024-03-12 | Johnson Sabrina Martucci | Buy | 750 000 | Employee Stock Option (right to buy) |
2024-03-12 | Haring-layton Mardee | Buy | 290 000 | Employee Stock Option (right to buy) |
2024-01-26 | Haring-layton Mardee | Sell | 3 500 | Employee Stock Option (right to buy) |
2024-01-26 | Haring-layton Mardee | Sell | 30 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
79.17 |
Last 91 transactions |
Buy: 10 072 923 | Sell: 492 500 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.512 (-6.74% ) |
Volume | 0.477 mill |
Avg. Vol. | 0.420 mill |
% of Avg. Vol | 113.64 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.